A
Armen B. Shanafelt
Researcher at Eli Lilly and Company
Publications - 8
Citations - 3490
Armen B. Shanafelt is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: FGF21 & Glucose uptake. The author has an hindex of 8, co-authored 8 publications receiving 3199 citations. Previous affiliations of Armen B. Shanafelt include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
FGF-21 as a novel metabolic regulator
Alexei Kharitonenkov,Tatiyana L. Shiyanova,Anja Koester,Amy M. Ford,Radmila Micanovic,Elizabeth Galbreath,George E. Sandusky,Lisa Janine Hammond,Julie S. Moyers,Owens Rebecca Anne,Jesper Gromada,Joseph T. Brozinick,Eric D. Hawkins,Victor J. Wroblewski,De Shan Li,Farrokh Mehrbod,S. Richard Jaskunas,Armen B. Shanafelt +17 more
TL;DR: It is concluded that FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Journal ArticleDOI
The Metabolic State of Diabetic Monkeys Is Regulated by Fibroblast Growth Factor-21
Alexei Kharitonenkov,Victor J. Wroblewski,Anja Koester,Yun-Fei Chen,Cathleen K. Clutinger,Xenia T. Tigno,Barbara C. Hansen,Armen B. Shanafelt,Garret J. Etgen +8 more
TL;DR: Systemic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in genetically compromised diabetic rodents and led to significant improvements in lipoprotein profiles, including lowering of low-density lipop Protein cholesterol and raising of high-density Lipoprotein cholesterol.
Journal ArticleDOI
FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho.
Alexei Kharitonenkov,James D. Dunbar,Holly A. Bina,Stuart W. Bright,Julie S. Moyers,Chen Zhang,Liyun Ding,Radmila Micanovic,Sean F. Mehrbod,Michael D. Knierman,John E. Hale,Tamer Coskun,Armen B. Shanafelt +12 more
TL;DR: Results indicate that βKlotho and FGFRs form the cognate FGF‐21 receptor complex, mediating F GF‐21 cellular specificity and physiological effects.
Journal ArticleDOI
Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity.
Eric D. Berglund,Candice Y. Li,Holly A. Bina,Sara E. Lynes,M. Dodson Michael,Armen B. Shanafelt,Alexei Kharitonenkov,David H. Wasserman +7 more
TL;DR: FGF21 has potent glycemic effects caused by hepatic changes in glucose flux and improved insulin sensitivity, and its therapeutic potential is supported.
Journal ArticleDOI
Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases.
TL;DR: The specifics of FGF21 activities both in cell culture and in vivo, its potential as a target for diabetes, and insights into the molecular mechanisms of F GF21 metabolic actions will be discussed in this review.